On May 10, 2025, the “Inaugural Meeting and Academic Training Conference of the Specialized Committee on Clinical Trials of Drugs, Devices and Specialty Foods of Chengdu High-Tech Medical Association” was held in Chengdu, which was co-sponsored by the Chengdu High-Tech Medical Association and the West China Second Hospital of Sichuan University.

Nearly 200 experts, scholars and managers from medical institutions, pharmaceutical companies, CRO/SMO companies and ethics committees in and outside the province gathered in Hibiscus City to witness the establishment of the Specialized Committee. Through deliberation, the General Assembly democratically elected the main committee, deputy main committee and standing committee leadership of the Specialized Committee, Prof. Yu Qin of West China Second Hospital of Sichuan University served as the first chairman of the Specialized Committee, Prof. Ding Hong of Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Prof. He Lin of Sichuan Provincial People's Hospital, Prof. Yang Xiao of First People's Hospital Hospital of Chengdu, Prof. He Qin of Third People's Hospital of Chengdu, Prof. Wu Yongkang of the First People's Hospital of Jintang County, Prof. Jiang Feng from the Affiliated Hospital of Southwest Medical University, Prof. He Qingling from the Second People's Hospital of Yibin City, and Prof. Yao Ke from Chengdu Bite Pharmaceutical Co.

At the meeting, the approval for the establishment of the functional party group of the Specialized Committee on Clinical Trials of Drugs, Devices and Specialty Foods was read out. Among the 112 party members of the Specialized Committee, after recommendation and discussion, the Society agreed to form the functional party group of the Specialized Committee by Comrade Yu Qin, Comrade Cai Linrui, and Comrade Feng Shiyin, of which Comrade Yu Qin is the leader of the working group, Comrade Cai Linrui is responsible for the disciplinary inspection and organization work, and Comrade Feng Shiyin is responsible for the publicity work. Propaganda work. Comrade Yu Qin led all the members in the party class to study the Eight Provisions of the Central Committee.

The academic training meeting was officially opened with the speeches of Zhang Lingliang, Vice President of West China Second Hospital of Sichuan University, and Aihe, Vice President and Deputy Secretary of Chengdu Hi-Tech Medical Association, who emphasized that the establishment of the committee will “promote the high-quality transformation of clinical trials and build a platform for cross-field collaboration”. They emphasized that the establishment of the committee will “promote the high-quality transformation of clinical trials and build a platform for cross-field collaboration”, and hoped that the committee, under the leadership of the committee chairman, can be based in Chengdu and radiate across the country, contributing to the development of the medical cause.

With the main line of “standardization-innovation-collaboration”, the meeting focused on the four core directions of policies and regulations, quality management, ethical construction, information technology and industry trends to carry out in-depth discussions. More than 5,000 students participated in the online study to learn the key points and implementation management in clinical research. Combining the latest policy guidance and practice cases, the experts systematically analyzed the key points of regulation of medical device clinical trials and the landing path of GCP guidelines, and focused on the construction of quality management system, optimization of the function of ethical committees, the application of informatization tools in the improvement of trial efficiency, as well as the prospects and challenges of the digital transformation of clinical research. Through multi-dimensional academic collision, practical solutions were provided for the standardized development and innovative practice of the industry. Through case studies and panel discussions, participating experts unanimously emphasized that only by strengthening the awareness of standardization, promoting technological innovation, and deepening cross-disciplinary collaboration can we realize the improvement of quality and efficiency of clinical trials and the transformation of results.

The success of this meeting marks the key role of Chengdu Hi-Tech Medical Association's Specialized Committee on Clinical Trials of Drugs, Devices and Specialty Foods in promoting the standardization and innovative development of the industry. In the future, with the aim of “standardization and innovation”, the committee will continue to deepen cross-field collaboration, integrate industry resources, and help build an efficient and transparent clinical trial ecosystem. Through regular academic exchanges, technical training and policy advocacy, the Committee will provide lasting impetus for the high-quality development of clinical trials and accelerate the transformation of research results to benefit patients' health.